CANDEL THERAPEUTICS, INC. Net Change in Cash
CANDEL THERAPEUTICS, INC. (CADL) reported Net Change in Cash of $81.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $75.10M.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$10.49M.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$9.70M.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$10.80M, a 192.37% decline year-over-year.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $17.23M, a 74.38% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $67.24M.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$34.65M.
- CANDEL THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$12.74M, a 126.69% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $81.83M 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $75.10M 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $17.23M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$15.69M 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | -$1.97M 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | -$10.49M 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | $67.24M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$18.86M 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | -$13.96M 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$9.70M 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | -$34.65M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$27.07M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$18.16M 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | -$10.80M 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | -$12.74M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $5.62M 10-Q · filed 2023-11-09 | -$5.62M 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $3.98M 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | $11.69M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $47.75M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $53.49M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | -$10.58M 10-Q · filed 2022-08-05 | ||||
| 2021-03-31 | -$5.74M 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $29.87M 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $13.08M 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $15.32M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |